Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis.
about
Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.Alleviating anemia and thrombocytopenia in myelofibrosis patients.Safety considerations when treating myelofibrosis.Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients.A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependenceTherapeutic approaches in myelofibrosis.Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis.The new landscape of therapy for myelofibrosis.The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.Pacritinib: a new agent for the management of myelofibrosis?Myelofibrosis: an update on drug therapy in 2016.Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.Management of myelofibrosis: JAK inhibition and beyond.Primary myelofibrosis: current therapeutic options.Emerging therapeutic options for myelofibrosis: a Canadian perspective.Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.
P2860
Q33423956-E235BDFD-D607-4D9F-BAC8-99D26E2E96B0Q33430113-F1EB59C3-56FA-4ECB-817B-C0482B3E3C57Q33432285-E57FCAB7-98E4-4341-977C-4C20AFD1A04CQ36001930-A3795BFD-DB95-461B-8F3C-09B0A3A74A8FQ36162041-AB0205BB-DE1D-4768-99F6-4E89CBAC1B21Q37740928-73F88B8C-BD44-436C-8A0F-F74BAE0E878EQ37860336-6652A42A-F09A-484A-9A13-75B1560383CAQ38143243-8E05D013-7851-4BA6-BA3F-905BC857B0BBQ38150261-42963F70-F4CC-4579-A0B6-0782376D05F0Q38403573-CA0987B7-6E62-4E5A-8DAB-79E3A47C08ECQ38590232-1FB603F5-E71F-454F-8D75-99C7B7BA0535Q38989215-38292F32-98C3-48D4-817F-652D5A461A76Q39069010-80C1DC36-5D1F-4AEA-A86E-7657D9BD7879Q39232415-905C8221-20D9-4035-B0DF-E4A3BBD08233Q41186952-52CBF22B-8A05-45C6-BBF5-AB762AEEF561Q41627599-61097C21-8E9F-42C1-970E-9C0B4ECFABD5Q50042813-BA9D5A66-5B69-43E1-B570-7F2207D27A0A
P2860
Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Recombinant human erythropoiet ...... onic idiopathic myelofibrosis.
@en
Recombinant human erythropoiet ...... onic idiopathic myelofibrosis.
@nl
type
label
Recombinant human erythropoiet ...... onic idiopathic myelofibrosis.
@en
Recombinant human erythropoiet ...... onic idiopathic myelofibrosis.
@nl
prefLabel
Recombinant human erythropoiet ...... onic idiopathic myelofibrosis.
@en
Recombinant human erythropoiet ...... onic idiopathic myelofibrosis.
@nl
P2093
P2860
P356
P1433
P1476
Recombinant human erythropoiet ...... onic idiopathic myelofibrosis.
@en
P2093
Bourantas KL
Bourantas LK
Kapsali HD
P2860
P304
P356
10.1159/000097463
P577
2006-12-06T00:00:00Z